Actionable news
All posts from Actionable news
Actionable news in CEMI: Chembio Diagnostics, Inc.,

Chembio Expands Product Distribution through Exclusive Agreement with Isla Lab in the Caribbean

MEDFORD, N.Y., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution agreement with Isla Lab Caribbean, which covers twenty-five nations in the Caribbean, excluding Puerto Rico and the U.S. Virgin Islands.

The exclusive distribution agreement with Isla Lab Caribbean initially includes Chembio’s current products, which have met regulatory requirements to be marketed and sold in the Caribbean region: DPP® Zika IgM/IgG Assay, DPP® Micro Reader, DPP® HIV 1/2 Assay, DPP® HIV/Syphilis Assay, HIV 1/2 STAT-PAK® Assay, STAT-VIEW® HIV 1/2 Assay, and Chagas STAT-PAK® Assay. The agreement also includes future Chembio products, which are pending regulatory approval or in development, such as: DPP® Chikungunya IgM/IgG Assay, DPP® Dengue IgM/IgG Assay, and DPP® Zika/Chikungunya/Dengue IgM/IgG Combination Assay.

Chembio’s newest product, the DPP® Zika IgM/IgG Assay detects antibodies from a 10uL fingerstick sample and provides quantitative results in 20 minutes, using the Company’s patented Dual Path Platform (DPP®) technology. The DPP® Zika IgM/IgG Assay is the first POC Zika test to obtain CE mark, which allows Chembio to commercialize the test in 17 European countries as well as the Caribbean nations.

John Sperzel, Chembio's Chief Executive Officer, commented, “We are thrilled to expand the availability of our products through this exclusive distribution agreement with Isla Lab Caribbean, the largest diagnostics distributor in the Caribbean region, which represents a number of the most respected diagnostic companies in the world. Many of the tests we are developing on our patented DPP® technology are for the detection of viruses that...